

L Core Project R030D030604

O Details

| Projects | Name | Award | Publications | Repositories | Analytics |
|-----------------|--|--------------|----------------|----------------|--------------|
| 1R03OD030604-01 | Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing | \$297,000.00 | 8 publications | 0 repositories | 0 properties |

Publications

Published works associated with this project.

| ID | Title | Authors | R C R | SJ R | Cita tion s | Cit./ yea r | Journal | Publ ishe d | Upda ted |
|------------|--|----------------------|-------------|----------|-------------------|-------------------|-------------------------------|-------------------|-------------|
| 35337371 🗹 | Considerations and challenges for sexaware drug repurposing. | Jennifer L Fisher | 1. 51 | 2. 03 | 9 | 4.5 | Biology of Sex Differences | 2,02 2 | Sep 30, |

| | | 4 more Brittany N Lasseign e | | | | | | | 2024 (2 weeks ago) |
|---------------------|--|---|---|---------------|---|---|----------------------------------|-----------|---|
| 37217845 🖸 | Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and | Elizabet h J Wilk 9 more Brittany N Lasseign e | 0 | 1. 44 6 | 1 | 1 | Molecular Medicine | 2,02 | Sep 28, 2024 (3 weeks ago) |
| 37090499 ℃ DOI ♂ | Evaluating cancer cell line and patient- derived xenograft recapitulation of tumor and non-disease | Avery S Williams2 more Brittany N Lasseign e | 0 | 0 | 0 | 0 | bioRxiv | 2,02 | Sep 28, 2024 (3 weeks ago) |
| 36602970 Z | Ten simple rules for using public biological data for your research. | Vishal H Oza 9 more Brittany | 0 | 1. 65 2 | 2 | 2 | PLoS Computational Biology | 2,02 3 | Sep 28, 2024 (3 |

| | | N Lasseign e | | | | | | | weeks ago) |
|-----------------------------------|--|---|---|---------------|---|---|-------------------------|-----------|---|
| 37362157 ♂ DOI ♂ | Sex-biased gene expression and gene- regulatory networks of sex-biased adverse event drug targets | Jennifer L Fisher2 more Brittany N Lasseign e | 0 | 0 | 0 | 0 | bioRxiv | 2,02 3 | Sep 28, 2024 (3 weeks ago) |
| 38531616 ☑ DOI ☑ | Signature reversion of three disease- associated gene signatures prioritizes cancer drug repurposi | Jennifer L Fisher7 more Brittany N Lasseign e | 0 | 0. 78 9 | 0 | 0 | FEBS Open Bio | 2,02 4 | Sep 28, 2024 (3 weeks ago) |
| 37533331 🗗 DOI 🗗 | Evaluating cancer cell line and patient- derived xenograft recapitulation of tumor and non-disease | Avery S Williams2 more Brittany N Lasseign e | 0 | 0 | 3 | 3 | Cancer Rep (Hoboken) | 2,02 3 | Sep 28, 2024 (3 weeks ago) |

| 38167211 乙 DOI 乙 | Sex-biased gene expression and gene- regulatory networks of sex-biased adverse event drug targets | Jennifer L Fisher2 more Brittany N Lasseign e | 0 | 0. 71 | 0 | 0 | BMC pharmacology & toxicology | 2,02 4 | Sep 28, 2024 (3 weeks ago) |
|-----------------------------------|---|---|---|----------|---|---|--|-----------|---|
|-----------------------------------|---|---|---|----------|---|---|--|-----------|---|

Notes

RCR Relative Citation Ratio

SJR Scimago Journal Rank

Software repositories associated with this project. Cumulative Publications

Total: 8



Only the main /default branch is considered for metrics like # of commits.

of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

Analytics

Traffic metrics of websites associated with this project.

Notes

Active Users <u>Distinct users who visited the website</u> .

New Users <u>Users who visited the website for the first time</u> **.**

Engaged Sessions <u>Visits that had significant interaction</u> **?**.

"Top" metrics are measured by number of engaged sessions.

Generated on Oct 17, 2024

Developed with support from NIH Award U54 OD036472